Trial Profile
A 4-Period, Placebo-Controlled, Crossover Study to Evaluate the Utility and Feasibility of BOLD fMRI and Cerebral Blood Flow Measurements as Biomarkers for Cognition Enhancing Drugs (Donepezil and MK3134)
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 10 May 2022
Price :
$35
*
At a glance
- Drugs MK 3134 (Primary) ; Donepezil
- Indications Dementia
- Focus Therapeutic Use
- Sponsors Merck Sharp & Dohme
- 05 Nov 2014 New trial record